Association of human aryl hydrocarbon receptor gene polymorphisms with risk of lung cancer among cigarette smokers in a Chinese population

Pharmacogenetics and Genomics

Volumn 19, Issue 1, 2009, Pages 25-34

  Chen, Dan ^a   Tian, Tian ^c   Wang, Haifeng ^b   Liu, Hongliang ^a   Hu, Zhibin ^c   Wang, Yi ^a,b   Liu, Yanhong ^a,d   Ma, Hongxia ^c   Fan, Weiwei ^a   Miao, Ruifen ^c   Sun, Weiwei ^b   Qian, Ji ^a   Jin, Li ^a,b   Wei, Qingyi ^d   Shen, Hongbing ^c   Huang, Wei ^b   Lu, Daru ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^c Medical University   (China)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; CARCINOGEN; POLYCYCLIC AROMATIC HYDROCARBON;

ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CHINESE; CIGARETTE SMOKING; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; TOBACCO;

AMINO ACID SUBSTITUTION; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CHINA; FEMALE; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ARYL HYDROCARBON; RISK FACTORS; SMOKING;

NICOTIANA TABACUM;

EID: 58149262992     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328316d8d8     Document Type: Article

References (54)

1. Shields PG. Molecular epidemiology of smoking and lung cancer. Oncogene 2002; 21:6870-6876.
2. Tsou JA, Hagen JA, Carpenter CL, Laird-Offringa IA. DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene 2002; 21:5450-5461.
3. Nebert DW, McKinnon RA, Puga A. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol 1996; 15:273-280.
4. Taningher M, Malacarne D, Izzotti A, Ugolini D, Parodi S. Drug metabolism polymorphisms as modulators of cancer susceptibility. Mutat Res 1999; 436:227-261.
5. Bartsch H, Nair U, Risch A, Rojas M, Wikman H, Alexandrov K. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev 2000; 9:3-28.
6. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999;91:1194-1210.
7. Rowland JC, Gustaffson JA. Aryl hydrocarbon receptor-mediate signal transduction. Crit Rev Toxicol 1997; 27:109-134.
8. Nebert DW, Dalton TP, Okey AB, Gonzalez FJ. Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem 2004; 279:23847-23850.
9. Uno S, Dalton TP, Dragin N, Curran CP, Derkenne S, Miller ML, et al. Oral benzo[a]pyrene in Cyp1 knockout mouse lines: CYP1A1 important in detoxication, CYP1B1 metabolism required for immune damage independent of total-body burden and clearance rate. Mol Pharmacol 2006; 69:1103-1114.
10. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995; 30:445-600.
11. Schrenk D. Impact of dioxin-type induction of drug-metabolizing enzymes on the metabolism of endo- and xenobiotics. Biochem Pharmacol 1998; 55:1155-1162.
12. Phillips DH. Fifty years of benzo(a)pyrene. Nature 1983; 303:468-472.
13. Stansbury KH, Flesher JW, Gupta RC. Mechanism of aralkyl-DNA adduct formation from benzo[a]pyrene in vivo. Chem Res Toxicol 1994; 7:254-259.
14. Shimizu Y, Nakatsuru Y, Ichinose M, Takahashi Y, Kume H, Mimura J, et al. Benzo[a]pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor. Proc Natl Acad Sci U S A 2000; 97:779-782.
15. Revel A, Raanani H, Younglai E, Xu J, Rogers I, Han R, et al. Resveratrol, a natural aryl hydrocarbon receptor antagonist, protects lung from DNA damage and apoptosis caused by benzo[a]pyrene. J Appl Toxicol 2003; 23:255-261.
16. Okey AB, Vella LM, Harper PA. Detection and characterization of a low affinity form of cytosolic Ah receptor in livers of mice nonresponsive to induction of cytochrome P1-450 by 3-methylcholanthrene. Mol Pharmacol 1989;35:823-830.
17. Nebert DW. The Ah locus: genetic differences in toxicity, cancer, mutation, and birth defects. Crit Rev Toxicol 1989; 20:153-174.
18. Poland A, Palen D, Glover E. Analysis of the four alleles of the murine aryl hydrocarbon receptor. Mol Pharmacol 1994; 46:915-921.
19. Shields PG. Molecular epidemiology of lung cancer. Ann Oncol 1999; 10(Suppl5):S7-S11.
20. Harris CC, Autrup H, Connor RD, Barrett LA, McDowell EM, Trump BF. Interindividual variation in binding of benzo[a]pyrene to DNA in cultured human bronchi. Science 1976; 194:1067-1069.
21. Willey JC, Coy EL, Frampton MW, Torres A, Apostolakos MJ, Hoehn G, et al. Quantitative RT-PCR measurement of cytochromes P450 1A1, 1B1, and 2B7, microsomal epoxide hydrolase, and NADPH oxidoreductase expression in lung cells of smokers and nonsmokers. Am J Respir Cell Mol Biol 1997; 17:114-124.
22. Kellermann G, Cantrell E, Shaw CR. Variations in extent of aryl hydrocarbon hydroxylase induction in cultured human lymphocytes. Cancer Res 1973; 33:1654-1656.
23. Nebert DW, Jensen NM. The Ah locus: genetic regulation of the metabolism of carcinogens, drugs, and other environmental chemicals by cytochrome P-450-mediated monooxygenases. CRC Crit Rev Biochem 1979; 6:401-437.
24. Kouri RE, McKinney CE, Slomiany DJ, Snodgrass DR, Wray NP, McLemore TL Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryopreserved lymphocytes. Cancer Res 1982;42:5030-5037.
25. Hu Z, Wang H, Shao M, Jin G, Sun W, Wang Y, et al. Genetic variants in MGMT and risk of lung cancer in Southeastern Chinese: a haplotype-based analysis. Hum Mutat 2007; 28:431-440.
26. Chen D, Jin G, Wang Y, Wang H, Liu H, Liu Y, et al. Genetic variants in peroxisome proliferator-activated receptor-gamma gene are associated with risk of lung cancer in a Chinese population. Carcinogenesis 2008; 29:342-350.
27. Lewontin RC. On measures of gametic disequilibrium. Genetics 1988; 120:849-852.
28. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, et al. The structure of haplotype blocks in the human genome. Science 2002; 296:2225-2229.
29. Barrett JC, Fry B, Mailer J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21:263-265.
30. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002; 70:425-434.
31. Hahn ME. The aryl hydrocarbon receptor: a comparative perspective. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1998; 121:23-53.
32. Karchner SI, Franks DG, Powell WH, Hahn ME. Regulatory interactions among three members of the vertebrate aryl hydrocarbon receptor family: AHR repressor, AHR1, and AHR2. J Biol Chem 2002; 277:6949-6959.
33. Harper PA, Wong JY, Lam MS, Okey AB. Polymorphisms in the human AH receptor. Chem Biol Interact 2002; 141:161-187.
34. Martey CA, Baglole CJ, Gasiewicz TA, Sime PJ, Phipps RP The aryl hydrocarbon receptor is a regulator of cigarette smoke induction of the cyclooxygenase and prostaglandin pathways in human lung fibroblasts. Am J Physiol Lung Cell Mol Physiol 2005; 289:L391-L399.
35. Marlowe JL, Puga A. Aryl hydrocarbon receptor, cell cycle regulation, toxicity, and tumorigenesis. J Cell Biochem 2005; 96:1174-1184.
36. Senft AP Dalton TR Nebert DW, Genter MB, Puga A, Hutchinson RJ, et al. Mitochondrial reactive oxygen production is dependent on the aromatic hydrocarbon receptor. Free Radic Biol Med 2002; 33:1268-1278.
37. Poland A, Palen D, Glover E. Tumour promotion by TCDD in skin of HRS/J hairless mice. Nature 1982; 300:271-273.
38. Chang JT, Chang H, Chen PH, Lin SL, Lin P. Requirement of aryl hydrocarbon receptor overexpression for CYP1B1 up-regulation and cell growth in human lung adenocarcinomas. Clin Cancer Res 2007; 13:38-45.
39. Kawajiri K, Watanabe J, Eguchi H, Nakachi K, Kiyohara C, Hayashi S. Polymorphisms of human Ah receptor gene are not involved in lung cancer. Pharmacogenetics 1995; 5:151-158.
40. Cauchi S, Stucker I, Solas C, Laurent-Puig P, Cenee S, Hemon D, et al. Polymorphisms of human aryl hydrocarbon receptor (AhR) gene in a French population: relationship with CYP1A1 inducibility and lung cancer. Carcinogenesis 2001; 22:1819-1824.
41. Kim JH, Kim H, Lee KY, Kang JW, Lee KH, Park SY, et al. Aryl hydrocarbon receptor gene polymorphisms affect lung cancer risk. Lung Cancer 2007; 56:9-15.
42. Wu X, Zhao H, Amos CI, Shete S, Makan N, Hong W, et al. p53 Genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst 2002; 94:681-690.
43. Lee KM, Choi JY, Park SK, Chung HW, Ann B, Yoo KY, et al. Genetic polymorphisms of ataxia telangiectasia mutated and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2005; 14:821-825.
44. Hu Z, Shao M, Yuan J, Xu L, Wang F, Wang Y, et al. Polymorphisms in DNA damage binding protein 2 (DDB2) and susceptibility of primary lung cancer in the Chinese: a case-control study. Carcinogenesis 2006; 27:1475-1480.
45. Ma H, Xu L, Yuan J, Shao M, Hu Z, Wang F, et al. Tagging single nucleotide polymorphisms in excision repair cross-complementing group 1 (ERCC1) and risk of primary lung cancer in a Chinese population. Pharmacogenet Genomics 2007; 17:417-423.
46. Brennan P. Gene-environment interaction and etiology of cancer: what does it mean and how can we measure it? Carcinogenesis 2002; 23:381-387.
47. Smart J, Daly AK. Variation in induced CYP1A1 levels: relationship to CYP1A1, Ah receptor and GSTM1 polymorphisms. Pharmacogenetics 2000; 10:11-24.
48. Smith GB, Harper PA, Wong JM, Lam MS, Reid KR, Petsikas D, et al. Human lung microsomal cytochrome P4501A1 (CYP1A1) activities: impact of smoking status and CYP1A1, aryl hydrocarbon receptor, and glutathione S-transferase M1 genetic polymorphisms. Cancer Epidemiol Biomarkers Prev 2001; 10:839-853.
49. Anttila S, Lei XD, Elovaara E, Karjalainen A, Sun W, Vainio H, et al. An uncommon phenotype of poor inducibility of CYP1A1 in human lung is not ascribable to polymorphisms in the AHR, ARNT, or CYP1A1 genes. Pharmacogenetics 2000; 10:741-751.
50. Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, Zaridze D, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008; 452:633-637.
51. Thorgeirsson TE, Geller F, Sulem R Rafnar T, Wiste A, Magnusson KP, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008; 452:638-642.
52. Amos CI, Wu X, Broderick R Gorlov IP, Gu J, Eisen T, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 2008; 40:616-622.
53. Altshuler D, Daly M. Guilt beyond a reasonable doubt. Nat Genet 2007; 39:813-815.
54. Chanock SJ, Hunter DJ. Genomics: when the smoke clears. Nature 2008; 452:537-538.